. Author manuscript; available in PMC: 2015 Oct 1.

Published in final edited form as: Eur J Gastroenterol Hepatol. 2014 Oct;26(10):1073–1082. doi: 10.1097/MEG.0000000000000152

Table 2. Comorbidity and medication use characteristics of a U.S. chronic HCV population in a commercial insurance database, 2006-2010.

	2006	2007	2008	2009	2010	Weighted Average
Enrollees with pharmacy benefit, n	(53,461 individuals, 79,185 cross-sections)
Enrollees with pharmacy benefit, n	11,424	11,517	19,379	18,882	17,983	(sum) 79,185

HCV Treated
Ribavirin + interferon, %	24.8	21.9	19.1	18.4	15.7	19.4

Comorbidity Measures^†
CCI: Treated, mean	1.7	1.7	1.9	2.0	2.1	1.9
CCI: Untreated, mean	2.1	2.2	2.3	2.5	2.6	2.4
Number of distinct medications per capita: Treated, mean	11.5	11.3	11.3	11.5	11.5	11.4
Number of distrinct medications per capita: Untreated, mean	8.7	9.0	8.5	9.2	9.3	9.0

Abbreviations: HCV, Hepatitis C virus; CCI, Charlson Comorbidity Index

^†

Treated: received ribavirin + PEG-interferon or interferon alfacon in a given year; Untreated: did not receive ribavirin + peg-interferon or interferon alfacon in a given year